Article Keyword Videos to Watch
Click on the image to start the video.
Images - Links - Articles
PPD Names Sara Vidmar Executive Director of PPD Medical Device
WILMINGTON, N.C. (February 1, 2006) – PPD, Inc. (Nasdaq: PPDI) today announced the appointment of Sara Vidmar as executive director of PPD Medical Device, its division providing clinical trial and post-market services to medical device companies, including device manufacturers and biopharmaceutical companies developing adjunctive therapies.
Vidmar will oversee a portfolio of services that includes study design, regulatory consulting, global trial management, clinical monitoring, data management, biostatistics and document development. The division offers device development in a broad array of therapeutic areas including cardiovascular, endovascular, neurology, orthopedics and wound therapies.
"Sara's leadership skills and extensive medical device experience are an excellent fit for PPD Medical Device," said Susan Atkinson, vice president of biostatistics and data management at PPD. "We are delighted to be able to offer our clients her broad knowledge of medical device development along with our strengths in regulatory, clinical, biostatistics and data management."
Vidmar most recently served as director, clinical research, in the division of cardiac surgery at St. Jude Medical Center in Saint Paul, Minn. Previously she served as clinical program manager responsible for premarket devices and drug/device combinations at Boston Scientific Corporation. Her professional experience also includes medical device development and sales experience with Magellan Medical Services, Inc. and Empi, Inc.
Revenues in the medical device and equipment market were approximately 6.2 billion in 2003 and were projected to grow 6.5 percent over the next three years according to a report by Frost & Sullivan.
PPD is a leading global contract research organization providing discovery and development services, market development expertise and compound partnering programs. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 28 countries and more than 8,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help its clients and partners maximize returns on their R&D investments and accelerate the delivery of safe and effective therapeutics to patients. For more information, visit our Web site at http://www.ppdi.com.
Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions about the anticipated value and contributions of the above-named employee and the prospects for our medical device business, contained in this news release are forward-looking statements that involve a number of risks and uncertainties. Although PPD attempts to be accurate in making those forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. In addition, other important factors which could cause results to differ materially include the following: the ability to attract and retain key personnel; economic conditions and outsourcing trends in the pharmaceutical, biotechnology and medical device industries; competition within the outsourcing industry; continued success in sales growth; loss of large contracts; dependence on collaborative relationships; rapid technological advances that make our products and services less competitive; risks associated with acquisitions and investments; and the other risk factors set forth from time to time in the SEC filings for PPD, copies of which are available free of charge upon request from the PPD investor relations department.
About the Author: News brought to you by PPD, an international contract research organization specializing in clinical trial management for the pharmaceutical, biotechnology, and medical industries.